Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Finished

CNECT-VAX C- and N-terminal Epitope Conjugate immune Cell Targeted Vaccines

Coordinator
Stichting Radboud Universitair Medisch Centrum, Netherlands
Runs
1 June 2022 to 30 November 2023
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069163

What the project is doing

In the project's own words, from its summary on CORDIS.

CNECT-VAX will validate the technical and commercial feasibility of a new cancer vaccine platform that uses nanobodies targeting dendritic cells to co-deliver antigens in vivo. As of 2019, cancer affects over 19 million people worldwide and results in almost 10 million death annually, however, the treatment of patients remains a challenge. Immunotherapy options including dendritic cell (DC) based vaccines have become available, but the clinical efficacy of such treatment remains very modest and restricted to patient subsets.

To overcome the limitations in the current state-of-art solutions and break barriers to achieve higher clinical efficacy, Dr. Martijn Verdoes proposes a novel molecular vaccine strategy that effectively delivers target antigens to DCs in vivo in the patient to concomitantly induce robust synergistic CD4+ and CD8+ T cell responses. The technical feasibility of CNECT-VAX will be assessed both in vitro and in vivo, using monocyte-derived human dendritic cells (MoDC) and a mouse model containing humanized DCs respectively.

In both systems, the functionality of DCs and the consequent T cell activation and immune responses will be measured. Subsequently, commercial feasibility will be determined by verifying IP position and strategy, performing in-depth market and competitor analyses, and finally consolidating these into a business plan to establish the best path to commercialization. Successful commercialization of CNECT-VAX could reduce the profound socioeconomic burden of cancer, extend and improve the lives of patients, provide the pharmaceutical industry with further collaborative opportunities, and stimulate further scientific research based on this platform to treat other pathogenic diseases.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI